QUANTAMATRIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,770 KRW | +5.16% |
|
+2.86% | -19.10% |
| Sales 2022 | 1.29B 935K | Sales 2023 | 3.12B 2.27M | Capitalization | 77.06B 56.03M |
|---|---|---|---|---|---|
| Net income 2022 | -19.24B -13.99M | Net income 2023 | -21.56B -15.67M | EV / Sales 2022 | 35.1 x |
| Net cash position 2022 | 30.98B 22.52M | Net cash position 2023 | 8.9B 6.47M | EV / Sales 2023 | 21.9 x |
| P/E ratio 2022 |
-3.96
x | P/E ratio 2023 |
-3.57
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.02% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.16% | ||
| 1 week | +2.86% | ||
| Current month | -9.38% | ||
| 1 month | -10.24% | ||
| 3 months | -17.60% | ||
| 6 months | -16.22% | ||
| Current year | -19.10% |
1 week
3 455.00
4 200.00
1 month
3 360.004 305.00
Current year
3 360.006 080.00
1 year
3 360.007 900.00
3 years
3 360.0022 900.00
5 years
3 360.0031 650.00
10 years
3 360.0031 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Hoon Kwon
FOU | Founder | 49 | 10-11-28 |
Jae-Hoon Kwon
DFI | Director of Finance/CFO | 47 | - |
Dong-Young Kim
CTO | Chief Tech/Sci/R&D Officer | 49 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Won-Hee Seol
BRD | Director/Board Member | 62 | - |
Sung-Hoon Kwon
FOU | Founder | 49 | 10-11-28 |
Jae-Hoon Kwon
DFI | Director of Finance/CFO | 47 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3,770 | +5.16% | 438,297 |
| 24-04-25 | 3,585 | -0.83% | 11,641 |
| 24-04-24 | 3,615 | -1.36% | 24,802 |
| 24-04-23 | 3,665 | +0.14% | 15,892 |
| 24-04-22 | 3,660 | -0.14% | 14,109 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
QuantaMatrix Inc is a Korean-based company engaged in the development and production of in vitro diagnostics (IVD) medical devices. The Company's main products include a multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, rapid antituberculosis susceptibility testing kits, and others. In addition, the Company sells covid kits and engages in research and development of microbial diagnostic products.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.10% | 43.17M | |
| +0.89% | 12.59B | |
| -10.29% | 7.42B | |
| +1.78% | 5.35B | |
| -1.16% | 4.51B | |
| +5.74% | 4.47B | |
| -50.70% | 3.21B | |
| +12.21% | 2.71B | |
| -16.13% | 1.96B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- A317690 Stock
